CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porters five force analysis
3.4.Top player positioning, 2019

3.4.1.Breast Cancer
3.4.2.All Cancer Types

3.5.Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in demand for safe and non-invasive procedures
3.5.1.2.Surge in global prevalence rate of breast cancer
3.5.1.3.Advantages of breast cancer liquid biopsy tests over traditional tests

3.5.2.Restraint

3.5.2.1.Lack of access and awareness in underdeveloped countries

3.5.3.Opportunity

3.5.3.1.High growth potential in emerging markets

3.5.4.Impact analysis

3.6.Pricing analysis
3.7.Reimbursement scenario
3.8.Clinical validations
3.9.Regulatory landscape
3.10.List of approved liquid biopsy tests

CHAPTER 4:BREAST CANCER LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE

4.1.Overview

4.1.1.Market size and forecast

4.2.Reagent kits

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Instruments

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Services

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER

5.1.Overview

5.1.1.Market size and forecast

5.2.Circulating tumor cells

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Extracellular vesicles

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

5.4.Circulating tumor DNA

5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country

CHAPTER 6:BREAST CANCER LIQUID BIOPSY MARKET, BY APPLICATION

6.1.Overview

6.1.1.Market size and forecast

6.2.Diagnostics

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Prognostics

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Risk assessment

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:BREAST CANCER LIQUID BIOPSY MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. breast cancer liquid biopsy market, by product & service
7.2.2.1.2.U.S. breast cancer liquid biopsy market, by circulating biomarker
7.2.2.1.3.U.S. breast cancer liquid biopsy market, by application

7.2.2.2.Canada

7.2.2.2.1.Canada breast cancer liquid biopsy market, by product & service
7.2.2.2.2.Canada breast cancer liquid biopsy market, by circulating biomarker
7.2.2.2.3.Canada breast cancer liquid biopsy market, by application

7.2.2.3.Mexico

7.2.2.3.1.Mexico breast cancer liquid biopsy market, by product & service
7.2.2.3.2.Mexico breast cancer liquid biopsy market, by circulating biomarker
7.2.2.3.3.Mexico breast cancer liquid biopsy market, by application

7.2.3.North America market size and forecast, by product & service
7.2.4.North America market size and forecast, by circulating biomarker
7.2.5.North America market size and forecast, by application

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany breast cancer liquid biopsy market, by product & service
7.3.2.1.2.Germany breast cancer liquid biopsy market, by circulating biomarker
7.3.2.1.3.Germany breast cancer liquid biopsy market, by application

7.3.2.2.France

7.3.2.2.1.France breast cancer liquid biopsy market, by product & service
7.3.2.2.2.France breast cancer liquid biopsy market, by circulating biomarker
7.3.2.2.3.France breast cancer liquid biopsy market, by application

7.3.2.3.UK

7.3.2.3.1.UK breast cancer liquid biopsy market, by product & service
7.3.2.3.2.UK breast cancer liquid biopsy market, by circulating biomarker
7.3.2.3.3.UK breast cancer liquid biopsy market, by application

7.3.2.4.Italy

7.3.2.4.1.Italy breast cancer liquid biopsy market, by product & service
7.3.2.4.2.Italy breast cancer liquid biopsy market, by circulating biomarker
7.3.2.4.3.Italy breast cancer liquid biopsy market, by application

7.3.2.5.Spain

7.3.2.5.1.Spain breast cancer liquid biopsy market, by product & service
7.3.2.5.2.Spain breast cancer liquid biopsy market, by circulating biomarker
7.3.2.5.3.Spain breast cancer liquid biopsy market, by application

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe breast cancer liquid biopsy market, by product & service
7.3.2.6.2.Rest of Europe breast cancer liquid biopsy market, by circulating biomarker
7.3.2.6.3.Rest of Europe breast cancer liquid biopsy market, by application

7.3.3.Europe market size and forecast, by product & service
7.3.4.Europe market size and forecast, by circulating biomarker
7.3.5.Europe market size and forecast, by application

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan breast cancer liquid biopsy market, by product & service
7.4.2.1.2.Japan breast cancer liquid biopsy market, by circulating biomarker
7.4.2.1.3.Japan breast cancer liquid biopsy market, by application

7.4.2.2.China

7.4.2.2.1.China breast cancer liquid biopsy market, by product & service
7.4.2.2.2.China breast cancer liquid biopsy market, by circulating biomarker
7.4.2.2.3.China breast cancer liquid biopsy market, by application

7.4.2.3.India

7.4.2.3.1.India breast cancer liquid biopsy market, by product & service
7.4.2.3.2.India breast cancer liquid biopsy market, by circulating biomarker
7.4.2.3.3.India breast cancer liquid biopsy market, by application

7.4.2.4.Rest of Asia-Pacific

7.4.2.4.1.Rest of Asia-Pacific breast cancer liquid biopsy market, by product & service
7.4.2.4.2.Rest of Asia-Pacific breast cancer liquid biopsy market, by circulating biomarker
7.4.2.4.3.Rest of Asia-Pacific breast cancer liquid biopsy market, by application

7.4.3.Asia-Pacific market size and forecast, by product & service
7.4.4.Asia-Pacific market size and forecast, by circulating biomarker
7.4.5.Asia-Pacific market size and forecast, by application

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America breast cancer liquid biopsy market, by product & service
7.5.2.1.2.Latin America breast cancer liquid biopsy market, by circulating biomarker
7.5.2.1.3.Latin America breast cancer liquid biopsy market, by application

7.5.2.2.Middle East

7.5.2.2.1.Middle East breast cancer liquid biopsy market, by product & service
7.5.2.2.2.Middle East breast cancer liquid biopsy market, by circulating biomarker
7.5.2.2.3.Middle East breast cancer liquid biopsy market, by application

7.5.2.3.Africa

7.5.2.3.1.Africa breast cancer liquid biopsy market, by product & service
7.5.2.3.2.Africa breast cancer liquid biopsy market, by circulating biomarker
7.5.2.3.3.Africa breast cancer liquid biopsy market, by application

7.5.3.LAMEA market size and forecast, by product & service
7.5.4.LAMEA market size and forecast, by circulating biomarker
7.5.5.LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

8.1.BIOCEPT INC.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product portfolio
8.1.5.Business performance
8.1.6.Key strategic moves and developments

8.2.F. HOFFMANN-LA ROCHE LTD. (FOUNDATION MEDICINE, INC.)

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.FLUXION BIOSCIENCES, INC.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio

8.4.MENARINI GROUP (MENARINI SILICON BIOSYSTEMS, INC.)

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Key strategic moves and developments

8.5.MYRIAD GENETICS, INC.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.NEOGENOMICS LABORATORIES, INC.

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments

8.7.QIAGEN N.V.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.SYSMEX CORPORATION

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.THERMO FISHER SCIENTIFIC, INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.GUARDANT HEALTH, INC.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments